Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

NCT06610643 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06610643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06610643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 21, 2024
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, immunocompromised, sars-cov-2